United Kingdom, 26th Apr 2025 – UK-based pet life science and pharmaceutical company Loyal Hound & Co. has announced a $2.3 billion (approximately KRW 3.1 trillion) investment to build manufacturing, logistics, and research hubs in China. The decision is viewed as a proactive response to the rapidly growing pet market in East Asia and part of a long-term strategy to mitigate political and institutional risks in the global supply chain.

The company plans to establish a 120,000 square meter “Pet Life Science Cluster” within a free trade zone near Shanghai. Key facilities will include a production site for high-performance animal formula products, a research institute dedicated to genomics-based longevity prediction algorithms, and a liaison center to collaborate with veterinary schools and hospitals across China.

Rather than focusing on short-term revenue growth, Loyal Hound emphasized that the investment is aimed at securing technological sovereignty and enhancing supply chain independence. The company stated that developing internal capabilities to manage risks in China is crucial to maintaining leadership in the global pet healthcare industry, especially amid continued US-China tensions and shifting European regulations.

As of 2024, China is home to more than 100 million registered pets, and the pet healthcare market is projected to exceed 500 billion yuan (approximately USD 70 billion) by 2025. However, the localization rate of high-function pharmaceuticals and animal formulas remains low, with a heavy dependence on imports. This has exposed structural vulnerabilities in supply stability and product reliability.

To address this issue, Loyal Hound plans to work with China’s veterinary academia to develop a China-specific life data model. The company will design longevity prediction algorithms and customized formulas tailored to the lifestyles of local pet owners. Rather than simply transplanting global technology, the approach is seen as a localized biotech adaptation strategy suited to the Chinese environment.

The investment also reflects a broader effort to internalize risk, particularly in response to China’s technology transfer policies, increased regulatory scrutiny of foreign enterprises, and its national strategy for tech self-reliance. Instead of pursuing a joint venture, Loyal Hound will establish a wholly owned subsidiary, allowing it to integrate production, distribution, and R&D under the control of its UK headquarters. This structure ensures complete ownership and strict control over equity and proprietary technologies.

To protect its core intellectual property, Loyal Hound will operate a dual-core R&D system. The core longevity prediction algorithms will remain encrypted and housed in the UK, while only de-identified data processing and algorithm execution will take place in China.

For More Information visit at Loyal Hound & Co. website.

United Kingdom, 26th Apr 2025 – Loyal Hound & Co., a UK-based pet life science company, has announced groundbreaking research results demonstrating the significant impact of its age-specific comprehensive formulas in reducing disease rates and promoting stable health throughout a pet’s lifespan.

Conducted by Loyal HL Bio LAB—Loyal Hound’s affiliated life science research institute—the study was based on a long-term Randomized Controlled Trial (RCT). It collected data from over 12,000 dogs across 14 clinical partner institutions in eight countries.

40% Reduction in Disease Risk: Evidence-Based Preventive Approach

According to the study, dogs that continuously consumed Loyal Hound’s age-specific formulas from the age of one showed a 40.7% lower incidence of diseases compared to control groups of the same breed and living environment. The results included delayed onset of chronic conditions (such as arthritis, liver dysfunction, and cardiovascular disorders), improved immune stability, and significantly reduced inflammation markers.

These preventive effects stem from formulations tailored to each life stage. The puppy formula enhances immunity and development, the adult formula supports metabolism and liver function, and the senior formula focuses on antioxidant and circulatory support. This strategic composition proactively addresses physiological vulnerabilities, promoting healthy aging.

A Strategic Shift: From Disease Treatment to Lifelong Prevention

This research stands out by validating a lifespan-oriented strategy aimed at preventing disease onset, rather than merely treating individual conditions. The researchers stated, “Transforming disease-related death into natural lifespan is key to longevity,” and they analyzed the formula’s effectiveness in delaying illness and boosting resilience.

This approach marks a paradigm shift in pet healthcare, contrasting with conventional short-term prescription models. The study suggests that the formula itself can serve as a proactive health management strategy.

Commercialization of Life Science-Based Longevity Planning

Building on the RCT findings, Loyal HL Bio LAB is preparing to expand the commercialization of its age-specific formulas while also developing additional solutions, such as healthspan prediction algorithms, disease risk scoring systems, and personalized formula-mapping platforms.

A Loyal Hound spokesperson commented, “We are committed to going beyond nutritional supplements—our mission is to design a full lifespan solution that prevents disease-related deaths and redefines pet wellness through applied life science.”

For More Information visit at Loyal Hound & Co. website.
 

United Kingdom, 26th Apr 2025 – UK-based pet life science company Loyal Hound & Co. has announced the construction of the world’s largest pet longevity research database, having secured life data from one million pets worldwide. The database is built on a vast collection of data sourced from nine countries across Europe, North America, and Asia.

It integrates and structures individual-level data for each pet, including genetic information, medical history, dietary and behavioral patterns, caregiver management habits, and environmental factors. A key feature of the database is the inclusion of lifetime health records based on genomics for over 100 dog and cat breeds, making it a precise observational dataset rather than simple statistical information. As such, it is considered a core infrastructure for AI-powered longevity prediction algorithms and personalized pet healthcare technologies.

Loyal Hound is currently analyzing the data to identify lifespan risk factors and disease patterns by country, breed, and environmental condition. Based on these insights, the company is advancing the development of customized animal formulas, commercializing AI-driven early diagnosis technologies, and refining individualized longevity prediction solutions.

The database also includes machine learning-based variables such as behavioral videos and biometric signals, paving the way for an integrated precision pet healthcare platform encompassing diagnosis, prediction, and treatment.

Loyal Hound stated that this longevity research database marks a turning point from intuition-based pet health management to a new era of data-driven scientific life planning, adding that it has secured the foundation to deliver personalized longevity management solutions to pet owners worldwide.

Based on this achievement, Loyal Hound plans to launch an open platform for its longevity prediction algorithm in 2026, release three new animal formula products, and begin beta testing of its AI early diagnosis solution. The company is also expanding its global partnerships with institutions such as the University of Oxford, Boston in the United States, and Heidelberg in Germany.

For More Information visit at Loyal Hound & Co. website.
 

United Kingdom, 26th Apr 2025 – Loyal Hound & Co., a UK-based pet life science company, has announced groundbreaking research results demonstrating the significant impact of its age-specific comprehensive formulas in reducing disease rates and promoting stable health throughout a pet’s lifespan.

Conducted by Loyal HL Bio LAB—Loyal Hound’s affiliated life science research institute—the study was based on a long-term Randomized Controlled Trial (RCT). It collected data from over 12,000 dogs across 14 clinical partner institutions in eight countries.

40% Reduction in Disease Risk: Evidence-Based Preventive Approach

According to the study, dogs that continuously consumed Loyal Hound’s age-specific formulas from the age of one showed a 40.7% lower incidence of diseases compared to control groups of the same breed and living environment. The results included delayed onset of chronic conditions (such as arthritis, liver dysfunction, and cardiovascular disorders), improved immune stability, and significantly reduced inflammation markers.

These preventive effects stem from formulations tailored to each life stage. The puppy formula enhances immunity and development, the adult formula supports metabolism and liver function, and the senior formula focuses on antioxidant and circulatory support. This strategic composition proactively addresses physiological vulnerabilities, promoting healthy aging.

A Strategic Shift: From Disease Treatment to Lifelong Prevention

This research stands out by validating a lifespan-oriented strategy aimed at preventing disease onset, rather than merely treating individual conditions. The researchers stated, “Transforming disease-related death into natural lifespan is key to longevity,” and they analyzed the formula’s effectiveness in delaying illness and boosting resilience.

This approach marks a paradigm shift in pet healthcare, contrasting with conventional short-term prescription models. The study suggests that the formula itself can serve as a proactive health management strategy.

Commercialization of Life Science-Based Longevity Planning

Building on the RCT findings, Loyal HL Bio LAB is preparing to expand the commercialization of its age-specific formulas while also developing additional solutions, such as healthspan prediction algorithms, disease risk scoring systems, and personalized formula-mapping platforms.

A Loyal Hound spokesperson commented, “We are committed to going beyond nutritional supplements—our mission is to design a full lifespan solution that prevents disease-related deaths and redefines pet wellness through applied life science.”

For More Information visit at Loyal Hound & Co. website.
 

United Kingdom, 26th Apr 2025 – UK-based pet life science and pharmaceutical company Loyal Hound & Co. has announced a $2.3 billion (approximately KRW 3.1 trillion) investment to build manufacturing, logistics, and research hubs in China. The decision is viewed as a proactive response to the rapidly growing pet market in East Asia and part of a long-term strategy to mitigate political and institutional risks in the global supply chain.

The company plans to establish a 120,000 square meter “Pet Life Science Cluster” within a free trade zone near Shanghai. Key facilities will include a production site for high-performance animal formula products, a research institute dedicated to genomics-based longevity prediction algorithms, and a liaison center to collaborate with veterinary schools and hospitals across China.

Rather than focusing on short-term revenue growth, Loyal Hound emphasized that the investment is aimed at securing technological sovereignty and enhancing supply chain independence. The company stated that developing internal capabilities to manage risks in China is crucial to maintaining leadership in the global pet healthcare industry, especially amid continued US-China tensions and shifting European regulations.

As of 2024, China is home to more than 100 million registered pets, and the pet healthcare market is projected to exceed 500 billion yuan (approximately USD 70 billion) by 2025. However, the localization rate of high-function pharmaceuticals and animal formulas remains low, with a heavy dependence on imports. This has exposed structural vulnerabilities in supply stability and product reliability.

To address this issue, Loyal Hound plans to work with China’s veterinary academia to develop a China-specific life data model. The company will design longevity prediction algorithms and customized formulas tailored to the lifestyles of local pet owners. Rather than simply transplanting global technology, the approach is seen as a localized biotech adaptation strategy suited to the Chinese environment.

The investment also reflects a broader effort to internalize risk, particularly in response to China’s technology transfer policies, increased regulatory scrutiny of foreign enterprises, and its national strategy for tech self-reliance. Instead of pursuing a joint venture, Loyal Hound will establish a wholly owned subsidiary, allowing it to integrate production, distribution, and R&D under the control of its UK headquarters. This structure ensures complete ownership and strict control over equity and proprietary technologies.

To protect its core intellectual property, Loyal Hound will operate a dual-core R&D system. The core longevity prediction algorithms will remain encrypted and housed in the UK, while only de-identified data processing and algorithm execution will take place in China.

For More Information visit at Loyal Hound & Co. website.

Alis Cerrahyan’s memoir The Sound of an Ordinary Life has received multiple awards and recognitions from a wide range of literary and cultural institutions. The book has been honoured for its contribution to personal narrative literature and its nuanced exploration of identity, memory, and emotional growth.

Among the awards received are The World’s Best Book Awards – Book of Excellence, the Literary Titan Gold Book Award, and the International Impact Book Awards. In addition, the book has been recognised by the Words Across the Waters Award, the Wordscape Wonders Award, and the Difference Maker Award, among others. These acknowledgments reflect the book’s broad appeal across different readerships and review panels.

Critics have consistently highlighted the book’s use of narrative voice and thematic consistency. Words Across the Waters described it as “an ability to hold space for contradiction, for disappointment, and for unexpected forms of hope,” while Wordscape Wonders noted that the book resists dramatization in favor of “emotional continuity.”

According to Excellence in Literature, “Cerrahyan’s memoir functions as a slow conversation with silence, avoiding spectacle while restoring personal agency.” The Pinnacle Review observed that “the project is not one of nostalgia but of recognition and repair.”

About the Book

The Sound of an Ordinary Life is a non-fiction work that explores identity, memory, and personal growth through an extended reflection between the author and her younger self. It addresses intergenerational trauma, cultural transition, and emotional development through narrative structure rather than formulaic resolution. It has been recognized by several literary and cultural institutions for its contribution to literature focused on healing and human experience.

To get a copy of the book, visit Amazon or Goodreads.

About the Author

Alis Cerrahyan is a writer whose work centers on emotional resilience, lived experience, and introspective narrative. She draws on her personal history, including her background as an immigrant and parent, to explore themes of growth, loss, and self-definition. Her first book has received wide recognition for its approach to personal storytelling and constructive reflection.

United Kingdom, 26th Apr 2025 – The European Union (EU) has designated the pet healthcare industry as a strategic export sector and is launching a full-scale export expansion policy covering 12 high-value items, including animal formulas. This initiative responds to growing global demand for functional pet products made in Europe and is expected to accelerate the international expansion of R&D-driven life science companies.

The EU Commission stated, “Animal formulas are a prime example of the shift from treatment-based veterinary prescriptions to preventive daily care,” adding that this category is driving demand as a substitute for pharmaceuticals and is a key sector with strong export competitiveness.

High-functionality formulas take root as daily treatment alternatives
According to a recent report released by the European Commission, animal formulas have posted an average annual export growth rate of 21 percent over the past five years, marking the highest growth among functional product categories replacing pharmaceuticals. Preventive formulas targeting immune health, joint and liver function, and aging have become widely prescribed through veterinary networks and are rapidly gaining traction in North America and Asia.

The report concluded that animal formulas have established themselves within the life sciences sector through a structural approach that focuses on prevention before risk rather than treatment after symptoms.

Technology-driven European companies pursue differentiation with life-stage based products
One of the companies drawing attention under this export policy is Loyal Hound & Co., a UK-based pet life science company. Loyal Hound is noted for going beyond simple nutritional supplements by predicting disease risk across life stages and offering age-specific comprehensive formulas, positioning itself as a longevity-focused technology company.

A report by the European Parliament stated, “High-tech companies like Loyal Hound are evolving from functional supplement suppliers into big-data-driven life management solution providers, aligning with the EU’s strategic export priorities.”

Eleven additional products designated—ushering in a new era of comprehensive pet healthcare exports
In addition to animal formulas, the EU has added 11 more pet healthcare products to its strategic export list, including antioxidant treats, oral care sticks, hair and skin care oils, and functional aroma diffusers for stress relief.

As a result, the traditional export structure centered on pet food and toys is being restructured around high-functionality and science-driven product lines, opening up new global expansion opportunities for technology-based companies.

As of 2025, Loyal Hound is expanding its age-specific formula product line into Asian and Middle Eastern markets in line with the EU’s export strategy and is also implementing a localization strategy based on life expectancy data for each country.

A new era of life science trade led by technology
This export strategy carries significance beyond simple market expansion. The EU is clearly positioning European technology-based pet healthcare products as a next-generation export industry that addresses the aging pet population, long-term safety demands, and the need for early disease detection.

An EU Commission representative stated, “The pet industry is no longer an emotional consumer market. We have entered an era in which science and technology design lifespans—and that technology is now the foundation of export competitiveness.”

For More Information visit at Loyal Hound & Co. website.

Miami, FL, United States, 26th Apr 2025 – Killer Whale Ventures has officially launched the Killer Whale Intelligence Platform (KWIP), an artificial intelligence-driven solution developed to support users navigating the cryptocurrency market. The platform offers a suite of digital asset management tools intended to assist a wide range of users, including individual investors, institutions, and portfolio managers.

KWIP incorporates machine learning algorithms to monitor market activity and execute trades. It also includes features for developing custom strategies, managing digital asset portfolios, and operating within non-custodial frameworks. The platform is designed to accommodate various user needs by offering both self-directed and professionally managed plans.

“KWIP represents a step forward in using AI to bring greater structure and analytical depth to digital asset trading,” said Dylan Shively, at Killer Whale Ventures. “Our aim is to provide a reliable and scalable platform that users can adapt to meet their specific investment approaches and risk profiles.”

The platform also includes compliance-focused tools to help users remain aligned with evolving regulatory standards across jurisdictions. In addition, Killer Whale Ventures maintains an online forum to encourage knowledge sharing among individuals interested in AI and digital finance.

About Killer Whale Ventures

Killer Whale Ventures is a financial technology company focused on developing artificial intelligence-based tools for digital asset management. The company draws inspiration from the adaptability and strategic behavior of the killer whale, applying these principles to its approach in delivering analytical solutions for the evolving crypto landscape.

Alis Cerrahyan’s memoir The Sound of an Ordinary Life has received multiple awards and recognitions from a wide range of literary and cultural institutions. The book has been honoured for its contribution to personal narrative literature and its nuanced exploration of identity, memory, and emotional growth.

Among the awards received are The World’s Best Book Awards – Book of Excellence, the Literary Titan Gold Book Award, and the International Impact Book Awards. In addition, the book has been recognised by the Words Across the Waters Award, the Wordscape Wonders Award, and the Difference Maker Award, among others. These acknowledgments reflect the book’s broad appeal across different readerships and review panels.

Critics have consistently highlighted the book’s use of narrative voice and thematic consistency. Words Across the Waters described it as “an ability to hold space for contradiction, for disappointment, and for unexpected forms of hope,” while Wordscape Wonders noted that the book resists dramatization in favor of “emotional continuity.”

According to Excellence in Literature, “Cerrahyan’s memoir functions as a slow conversation with silence, avoiding spectacle while restoring personal agency.” The Pinnacle Review observed that “the project is not one of nostalgia but of recognition and repair.”

About the Book

The Sound of an Ordinary Life is a non-fiction work that explores identity, memory, and personal growth through an extended reflection between the author and her younger self. It addresses intergenerational trauma, cultural transition, and emotional development through narrative structure rather than formulaic resolution. It has been recognized by several literary and cultural institutions for its contribution to literature focused on healing and human experience.

To get a copy of the book, visit Amazon or Goodreads.

About the Author

Alis Cerrahyan is a writer whose work centers on emotional resilience, lived experience, and introspective narrative. She draws on her personal history, including her background as an immigrant and parent, to explore themes of growth, loss, and self-definition. Her first book has received wide recognition for its approach to personal storytelling and constructive reflection.